VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 336-342

  Zhou, Zhitao ^a   Lu, Xiao ^a   Zhu, Ping ^a   Zhu, Wei ^b   Mu, Xia ^c   Qu, Rongmei ^a   Li, Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Chemokine; Hepatocellular carcinoma; VCC 1

Indexed keywords

CHEMOKINE; CISPLATIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR CORRELATED CHEMOKINE 1;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER TISSUE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EXPOSURE; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84862816362     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.160     Document Type: Article

References (38)

1. Rampone B., Schiavone B., Martino A., Viviano C., Confuorto G. Current management strategy of hepatocellular carcinoma. World J. Gastroenterol. 2009, 15:3210-3216.
2. Okuda K. Hepatocellular carcinoma. J. Hepatol. 2000, 32:225-237.
3. Duffy J.P., Hiatt J.R., Busuttil R.W. Surgical resection of hepatocellular carcinoma. Cancer J. 2008, 14:100.
4. Mizuta T., Ozaki I., Eguchi Y., Yasutake T., Kawazoe S., Fujimoto K., Yamamoto K. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment. Cancer 2006, 106:867-872.
5. Viola A., Luster A.D. Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 2008, 48:171-197.
6. Singh S., Sadanandam A., Singh R.K. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007, 26:453-467.
7. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
8. Albert Z. Chemokines in neoplastic progression. Semin. Cancer Biol. 2004, 14:181-185.
9. Roberts L.R. Chemokines as attractive targets in liver carcinogenesis. Am. J. Gastroenterol. 2005, 100:499-501.
10. Weinstein E., Head R., Griggs D., Sun D., Evans R., Swearingen M., Westlin M., Mazzarella R. VCC-1, a novel chemokine, promotes tumor growth. Biochem. Biophys. Res. Commun. 2006, 350:74-81.
11. Pisabarro M.T., Leung B., Kwong M., Corpuz R., Frantz G.D., Chiang N., Vandlen R., Diehl L.J., Skelton N., Kim H.S. Cutting edge: novel human dendritic cell-and monocyte-attracting chemokine-like protein identified by fold recognition methods. J. Immunol. 2006, 176:2069.
12. Hiraoka N., Yamazaki-Itoh R., Ino Y., Mizuguchi Y., Yamada T., Hirohashi S., Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011, 140:310-321. (e314).
13. Mu X., Chen Y., Wang S., Huang X., Pan H., Li M. Overexpression of VCC-1 gene in human hepatocellular carcinoma cells promotes cell proliferation and invasion. Acta Biochim. Biophys. Sin. 2009, 41:631-637.
14. Dreolini L., Takei F. Activation of LFA-1 by ionomycin is independent of calpain-mediated talin cleavage. Biochem. Biophys. Res. Commun. 2007, 356:207-212.
15. Kang S.-H., Lee H.-J., Jeong S.-J., Kwon H.-Y., Kim J.-H., Yun S.-M., Kim J.-H., Lee H.-J., Lee E.-O., Ahn K.S., Ahn K.S., Kim S.-H. Protective effect of Bojungbangdocktang on cisplatin-induced cytotoxicity and apoptosis in MCF-10A breast endothelial cells. Environ. Toxicol. Pharmacol. 2009, 28:430-438.
16. Hacker G. The morphology of apoptosis. Cell Tissue Res. 2000, 301:5-17.
17. Du D., Liu S., Chen J., Ju H., Lian H., Li J. Colloidal gold nanoparticle modified carbon paste interface for studies of tumor cell adhesion and viability. Biomaterials 2005, 26:6487-6495.
18. Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001, 2:129-134.
19. Zlotnik A. Chemokines and cancer. Int. J. Cancer 2006, 119:2026-2029.
20. Huang F., Geng X.P. Chemokines and hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:1832.
21. Chen T.H.-H., Chen C.-J., Yen M.-F., Lu S.-N., Sun C.-A., Huang G.-T., Yang P.-M., Lee H.-S., Duffy S.W. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int. J. Cancer 2002, 98:257-261.
22. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., Nakanishi K., Fujimoto I., Inoue A., Yamazaki H., Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993, 328:1797-1801.
23. Velázquez R.F., Rodríguez M., Navascués C.A., Linares A., Pérez R., Sotorríos N.G., Martínez I., Rodrigo L. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003, 37:520-527.
24. P. Ferenci, M. Fried, D. Labrecque, J. Bruix, M. Sherman, M. Omata, J. Heathcote, T. Piratsivuth, M. Kew, J.A. Otegbayo, S.S. Zheng, S. Sarin, S.S. Hamid, S.B. Modawi, W. Fleig, S. Fedail, A. Thomson, A. Khan, P. Malfertheiner, G. Lau, F.J. Carillo, J. Krabshuis, A. Le Mair, Hepatocellular carcinoma (HCC): a global perspective, J. Clin. Gastroenterol. 44 (2010) 239-245, 210.1097/MCG.1090b1013e3181d1046ef1092.
25. Lai E., Lau W. The continuing challenge of hepatic cancer in Asia. Surgeon 2005, 3:210-215.
26. Cha C.H., Ruo L., Fong Y., Jarnagin W.R., Shia J., Blumgart L.H., DeMatteo R.P. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann. Surg. 2003, 238:315.
27. Lau W.Y., Lai E. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat. Dis. Int. 2008, 7:237-257.
28. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
29. Llovet J.M., Real M.I., Monta a X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Sol R. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
30. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T.P., Fan S.T., Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
31. Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R., Schirlau K., Franken Kunkel P., Poremba C., Snyderman C., Klotz L.O. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int. J. Cancer 2006, 118:2147-2157.
32. Agostini M., Tucci P., Melino G. Cell death pathology: perspective for human diseases. Biochem. Biophys. Res. Commun. 2011, 414:451-455.
33. Ning Y., Manegold P.C., Hong Y.K., Zhang W., Pohl A., Lurje G., Winder T., Yang D., LaBonte M.J., Wilson P.M. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int. J. Cancer 2011, 128:2038-2049.
34. Kitadai Y., Haruma K., Mukaida N., Ohmoto Y., Matsutani N., Yasui W., Yamamoto S., Sumii K., Kajiyama G., Fidler I.J. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin. Cancer Res. 2000, 6:2735-2740.
35. Zhang Y., Zhao H., Zhao D., Sun L., Zhi Y., Wu X., Huang W., Da W. SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis. Leuk. Res. 2012, 36:281-286.
36. Mavier P., Martin N., Couchie D., Préaux A.M., Laperche Y., Zafrani E.S. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am. J. Pathol. 2004, 165:1969.
37. Bertran E., Caja L., Navarro E., Sancho P., Murillo M.M., Vinyals A., Fabregat I. Role of CXCR4/SDF-1 [alpha] in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-[beta]. Cell. Signal. 2009, 21:1595-1606.
38. Johnson E., Singh R., Johnson-Holiday C., Grizzle W., Partridge E., Lillard J., Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J. Ovarian Res. 2010, 3:15.